Cordlife Group Limited
Cordlife Group Limited (CLIFF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cliff · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Cordlife Group Limited (CLIFF) measures how much investors pay for each dollar of the company's trailing earnings. CLIFF's current PE ratio of N/A is calculated by dividing its stock price of $0.09 by its TTM earnings per share of -$0.02.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2011 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 13 fiscal years · Front-end computedMinQ1 · 25%15.4x
MedianQ3 · 75%58.0x
Max
At N/A, CLIFF's current P/E is lower than in 0% of its annual fiscal year readings over the past 13 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Diagnostics & Research · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Cordlife Group LimitedYou CLIFF | $23M | N/A | — | -$0.02 |
 Bonus BioGroup Ltd. BBIXF | $152M | N/A | — | -$0.04 |
 BioMark Diagnostics Inc. BMKDF | $42M | N/A | — | -$0.02 |
 Celyad Oncology S.A. CLYYF | $11M | 6.58x | — | $0.02 |
 Charlotte's Web Holdings, Inc. CWBHF | $67M | N/A | — | -$0.19 |
 Finch Therapeutics Group, Inc. FNCH | $12M | N/A | — | -$8.64 |
 ImpediMed Limited IPDQF | $11M | N/A | — | -$0.01 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.05 | — | |
2024-12-31 FY2024 | — | $-0.07 | — | |
2023-12-31 FY2023 | 28.73x | $0.01 | +86.0% | |
2022-12-31 FY2022 | 15.45x | $0.02 | +5.1% | |
2021-12-31 FY2021 | 14.70x | $0.02 | +3.5% | |
2020-12-31 FY2020 | 14.20x | $0.03 | -39.3% | |
2019-12-31 FY2019 | 23.40x | $0.02 | -55.3% | |
2018-12-31 FY2018 | 52.41x | $0.01 | -9.6% | |
2018-06-30 FY2018 | 57.96x | $0.01 | — | |
2017-06-30 FY2017 | — | $-0.01 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Cordlife Group Limited (CLIFF) measures how much investors pay for each dollar of the company's trailing earnings. CLIFF's current PE ratio of N/A is calculated by dividing its stock price of $0.09 by its TTM earnings per share of -$0.02.
Frequently asked questions
CLIFF pe ratio · 6 questionsCLIFF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.09 and TTM EPS of -$0.02. Data sourced from Financial Modeling Prep via CLIFF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Cordlife Group Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09